Table 2 Summary of the subgroup analysis results of NLR on OS and PFS/RFS.

From: Prognostic significance of neutrophil-to-lymphocyte ratio in prostate cancer: evidence from 16,266 patients

Outcome

Variable

No. of studies

No. of patients

Model

HR (95%CI)

Heterogeneity

Meta-regression P value

Ph

I2(%)

OS

All

11

14250

R

1.38(1.22–1.56)

0.002

64.1

 
 

PCa type

      

0.01

 

mCRPC

7

3826

F

1.44(1.32–1.57)

0.238

25

 
 

Localized PCa

3

9715

R

1.16(0.98–1.36)

0.109

54.9

 
 

All PCa

1

709

1.55(0.97–2.47)

 
 

Sample size

      

0.19

 

>400

7

13409

R

1.32(1.16–1.49)

0.005

67.8

 
 

<400

4

841

F

1.61(1.31–1.99)

0.252

26.6

 
 

NLR cut-off

      

0.756

 

≤3

6

4539

R

1.34(1.24–1.45)

0.009

67.3

 
 

>3

5

9711

R

1.18(1.06–1.31)

0.066

54.6

 

PFS/RFS

All

9

12541

R

1.24(1.05–1.46)

0.003

65.3

 
 

Ethnicity

       
 

Asian

3

1455

F

1.42(1.11–1.82)

0.345

6

 
 

Caucasian

6

11086

R

1.18(0.98–1.43)

0.003

72.3

 
 

PCa type

       
 

mCRPC

3

843

F

1.45(1.19–1.77)

0.37

0

 
 

Localized PCa

6

11698

R

1.16(0.97–1.39)

0.01

66.6

 
 

Sample size

       
 

>400

5

11837

R

1.28(1.00–1.65)

0.001

78.8

 
 

<400

4

704

F

1.14(0.98–1.33)

0.255

26.1

 
 

NLR cut-off

       
 

≤3

6

3721

F

1.17(1.06–1.29)

0.203

30.9

 
 

>3

3

8820

R

1.82(0.77–4.3)

0

87.3

 
  1. F: fixed-effects model; R: random-effects model.